US FDA Approves Ruxolitinib (Opzelura) to Treat Nonsegmental Vitiligo
The US Food and Drug Administration (FDA) has approved Incyte’s Ruxolitinib (Opzelura) cream 1.5 percent for the topical treatment of nonsegmental vitiligo in pediatric and adult patients above 12 years of age. The Opzelura is the first and only treatment approved by US FDA for repigmentation in patients with vitiligo, and it is the only […]
Continue Reading